Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/34757
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Salman, Andaç | - |
dc.contributor.author | Alper, Sibel | - |
dc.contributor.author | Atakan, Nilgün | - |
dc.contributor.author | Borlu, Murat | - |
dc.contributor.author | Canpolat, Filiz | - |
dc.contributor.author | Erdem, Teoman | - |
dc.contributor.author | Erdem, Yasemin | - |
dc.contributor.author | Gül, Ülker | - |
dc.contributor.author | Kartal, Selda Pelin | - |
dc.contributor.author | Koca, Rafet | - |
dc.contributor.author | Küçük, Özlem Su | - |
dc.date.accessioned | 2023-11-02T10:42:30Z | - |
dc.date.available | 2023-11-02T10:42:30Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.citation | Salman, A. vd. (2020). "Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology". Turkderm Turkish Archives of Dermatology and Venereology, 54(2), 71-75. | tr_TR |
dc.identifier.issn | 2717-6398 | - |
dc.identifier.issn | 2651-5164 | - |
dc.identifier.uri | https://doi.org/10.4274/turkderm.galenos.2020.80000 | - |
dc.identifier.uri | https://jag.journalagent.com/turkderm/pdfs/TURKDERM_54_2_71_75.pdf | - |
dc.identifier.uri | http://hdl.handle.net/11452/34757 | - |
dc.language.iso | en | en_US |
dc.publisher | Galenos Yayıncılık | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Dermatology | en_US |
dc.subject | Atopic dermatitis | en_US |
dc.subject | Covid-19 | en_US |
dc.subject | Treatment | en_US |
dc.subject | Urticaria | en_US |
dc.subject | Omalizumab | en_US |
dc.subject | Metaanalysis | en_US |
dc.subject | Atopik dermatit | tr_TR |
dc.subject | COVID-19 | tr_TR |
dc.subject | Dupilumab | tr_TR |
dc.subject | Tedavi | tr_TR |
dc.subject | Ürtiker | tr_TR |
dc.title | Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology | en_US |
dc.title.alternative | COVID-19 pandemisi süresince ürtiker ve atopik dermatitte sistemik tedavilerin kullanımına ilişkin öneriler: Türk Dermatoloji Derneği dermatoallerji çalışma grubu bildirisi | tr_TR |
dc.type | Letter | en_US |
dc.identifier.wos | 000544409600008 | tr_TR |
dc.identifier.scopus | 2-s2.0-85089913448 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-0144-3263 | tr_TR |
dc.identifier.startpage | 71 | tr_TR |
dc.identifier.endpage | 75 | tr_TR |
dc.identifier.volume | 54 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Turkderm Turkish Archives of Dermatology and Venereology | en_US |
dc.contributor.buuauthor | Başkan, Emel Bülbül | - |
dc.contributor.researcherid | AAH-1388-2021 | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.indexed.trdizin | TrDizin | tr_TR |
dc.subject.wos | Dermatology | en_US |
dc.indexed.wos | ESCI | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 6602518817 | tr_TR |
dc.subject.scopus | Skin; Allergic contact dermatitis; COVID-19 | en_US |
dc.subject.emtree | Azathioprine | en_US |
dc.subject.emtree | Cyclosporine | en_US |
dc.subject.emtree | Dupilumab | en_US |
dc.subject.emtree | Interleukin 1beta | en_US |
dc.subject.emtree | Interleukin 6 | en_US |
dc.subject.emtree | Methotrexate | en_US |
dc.subject.emtree | Mycophenolate mofetil | en_US |
dc.subject.emtree | Omalizumab | en_US |
dc.subject.emtree | Prednisolone | en_US |
dc.subject.emtree | Atopic dermatitis | en_US |
dc.subject.emtree | Coronavirus disease 2019 | en_US |
dc.subject.emtree | Cytokine storm | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hypertension | en_US |
dc.subject.emtree | Immunosuppressive treatment | en_US |
dc.subject.emtree | Immunotherapy | en_US |
dc.subject.emtree | Inflammation | en_US |
dc.subject.emtree | Letter | en_US |
dc.subject.emtree | Obesity | en_US |
dc.subject.emtree | Pandemic | en_US |
dc.subject.emtree | Randomized controlled trial (topic) | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Severe acute respiratory syndrome coronavirus 2 | en_US |
dc.subject.emtree | Shared decision making | en_US |
dc.subject.emtree | Systemic therapy | en_US |
dc.subject.emtree | Urticaria | en_US |
Appears in Collections: | Scopus TrDizin Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Başkan_vd_2020.pdf | 151.57 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License